Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC
IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.